Cingulate opened lower at $4.53, compared with its previous close of $4.64. In the last trading session, the stock traded between $4.40 and $4.63. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Cingulate is now worth
$ 0.42
Resulting in a loss of
$ 99.58 (99.58%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.17 (-3.56%)
Day High
$4.63
Day Low
$4.40
Day Open
$4.53
Prev Close
$4.64
Volume
63,806
1W Return
-1.28%
1M Return
-7.66%
3M Return
-13.93%
6M Return
-9.78%
1Y Return
21.93%
Fundamentals
Market Cap ($ Mn)
65
PE Ratio
-
PB Ratio
3.15
PEG Ratio
-
ROE
-451.15%
ROCE
-320.70%
EPS (TTM)
$-0.42
Investment Returns
1 Week
-1.28%
1 Month
-7.66%
3 Months
-13.93%
6 Months
-9.78%
9 Months
-31.89%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
2Jul
Cingulate Inc. added to Russell 3000E Index
Cingulate Inc. has been added to the Russell 3000E Index, effective July 02, 2026, enhancing visibility with institutional investors. CEO Shane J. Schaffer highlighted the move as a significant achievement for the company's evolution. Cingulate continues to advance its lead ADHD product candidate, CTx-1301, utilizing its proprietary Precision Timed Release (PTR) platform.
4mo ago
16Jun
Cingulate secures US patent for ADHD asset CTx-1301
Cingulate Inc. has secured its first company-owned U.S. patent for its lead asset CTx-1301, a treatment for Attention Deficit Hyperactivity Disorder (ADHD). The patent, issued by the United States Patent and Trademark Office on June 16, 2026, protects the drug's formulation and method of use through December 2042. This strengthens the company's intellectual property portfolio as it advances toward potential commercialization.
